Calliditas Therapeutics Logo

Calliditas Therapeutics

ISIN: SE0010441584 | Ticker: CALTX | LEI: 549300PVPZO8TNT76B58
Sector: Health CareSub-Industry: Pharmaceuticals
Country: Sweden

About Calliditas Therapeutics

Company Description

Calliditas is dedicated to expanding treatment options and establishing new standards of care for people with rare diseases. By drawing on our expertise in pharmaceutical product development and leveraging our strategic partnerships, we quickly and efficiently identify, develop, and market a pipeline of innovative medicines that can improve the lives of patients.

Recently, we successfully commercialized our lead candidate in the United States, and in collaboration with our partners, launched in Europe, with plans to seek approval in Asia.

Year founded

2004

Headquarters

Kungsbron 1, 11122 Stockholm – Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2019 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A N/A 1,463,908,000.00 1,459,910,000.00 1,952,973,000.00
Noncurrent Assets N/A N/A 427,057,000.00 447,138,000.00 540,770,000.00
Property Plant And Equipment N/A N/A 163,000.00 6,309,000.00 7,468,000.00
Current Assets N/A N/A 1,036,851,000.00 1,012,772,000.00 1,412,204,000.00
Inventories N/A N/A 0.00 889,000.00 3,647,000.00
Trade And Other Current Receivables N/A N/A N/A 0.00 78,703,000.00
Current Prepaid Expenses N/A N/A 17,746,000.00 45,032,000.00 70,741,000.00
Cash and cash equivalents 646,175,000.00 753,540,000.00 996,304,000.00 955,507,000.00 1,249,094,000.00
Other Current Assets N/A N/A 22,801,000.00 11,343,000.00 10,018,000.00
Equity And Liabilities N/A N/A 1,463,908,000.00 1,459,910,000.00 1,952,973,000.00
Equity 618,175,000.00 788,071,000.00 1,256,300,000.00 1,008,281,000.00 766,264,000.00
Issued Capital N/A N/A 1,998,000.00 2,094,000.00 2,383,000.00
Retained Earnings N/A N/A -918,596,000.00 -1,426,574,000.00 -1,836,317,000.00
Other Reserves N/A N/A -6,090,000.00 -26,979,000.00 9,307,000.00
Additional Paidin Capital N/A N/A 2,133,179,000.00 2,459,741,000.00 2,590,890,000.00
Equity Attributable To Owners Of Parent N/A N/A 1,210,491,000.00 1,008,281,000.00 766,264,000.00
Noncontrolling Interests N/A N/A 45,809,000.00 0.00 N/A
Noncurrent Liabilities N/A N/A 101,989,000.00 316,183,000.00 861,479,000.00
Noncurrent Provisions For Employee Benefits N/A N/A 8,296,000.00 3,182,000.00 884,000.00
Other Longterm Provisions N/A N/A 6,391,000.00 14,530,000.00 11,792,000.00
Noncurrent Interest Payable N/A N/A 0.00 189,164,000.00 713,030,000.00
Other Noncurrent Liabilities N/A N/A 878,000.00 0.00 4,350,000.00
Current Liabilities N/A N/A 105,619,000.00 135,446,000.00 325,231,000.00
Trade And Other Current Payables N/A N/A 53,827,000.00 67,971,000.00 160,404,000.00
Current Tax Liabilities Current N/A N/A 518,000.00 1,221,000.00 5,684,000.00
Current Accrued Expenses And Other Current Liabilities N/A N/A N/A 53,553,000.00 136,446,000.00
Other Current Liabilities N/A N/A 9,888,000.00 12,702,000.00 22,697,000.00
Line item in (sek) 01.01.2019/
01.01.2020
01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue From Contracts With Customers 184,829,000.00 874,000.00 229,347,000.00 802,879,000.00
Other Income 4,385,000.00 2,501,000.00 259,000.00 2,862,000.00
Profit Loss From Operating Activities -28,019,000.00 -379,720,000.00 -524,456,000.00 -421,943,000.00
Finance Income 926,000.00 547,000.00 20,336,000.00 50,195,000.00
Finance Costs 5,408,000.00 56,978,000.00 9,253,000.00 37,669,000.00
Profit Loss Before Tax -32,501,000.00 -436,151,000.00 -513,373,000.00 -409,417,000.00
Income Tax Expense Continuing Operations 77,000.00 360,000.00 -3,836,000.00 2,851,000.00
Profit (loss) -32,578,000.00 -436,511,000.00 -509,537,000.00 -412,268,000.00
Profit Loss Attributable To Owners Of Parent -32,578,000.00 -433,494,000.00 -500,293,000.00 -412,268,000.00
Profit Loss Attributable To Noncontrolling Interests 0.00 -3,017,000.00 -9,244,000.00 0.00
Line item in (sek) 01.01.2019 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -32,578,000.00 -436,511,000.00 -509,537,000.00 -412,268,000.00
Adjustments For Reconcile Profit Loss N/A 2,308,000.00 15,465,000.00 66,676,000.00 61,260,000.00
Adjustments For Decrease Increase In Inventories N/A 0.00 0.00 -949,000.00 -2,758,000.00
Adjustments For Reconcile Profit Loss N/A 2,308,000.00 15,465,000.00 66,676,000.00 61,260,000.00
Interest Paid Classified As Operating Activities N/A 325,000.00 393,000.00 5,432,000.00 35,252,000.00
Interest Received Classified As Operating Activities N/A 926,000.00 1,912,000.00 102,000.00 3,553,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A 0.00 528,000.00 3,949,000.00 7,392,000.00
Cash Flows From Used In Operating Activities N/A -71,011,000.00 -309,181,000.00 -461,588,000.00 -311,354,000.00
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A 0.00 172,602,000.00 0.00 0.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 118,000.00 0.00 6,588,000.00 2,512,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 16,066,000.00 0.00 16,066,000.00 0.00
Cash Flows From Used In Investing Activities N/A -18,072,000.00 -172,607,000.00 -24,340,000.00 -5,144,000.00
Payments From Changes In Ownership Interests In Subsidiaries N/A 0.00 82,172,000.00 49,303,000.00 0.00
Proceeds From Issuing Shares N/A 210,317,000.00 891,388,000.00 324,000,000.00 0.00
Payments To Acquire Or Redeem Entitys Shares N/A N/A 0.00 0.00 236,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 1,652,000.00 3,972,000.00 5,575,000.00 9,615,000.00
Cash Flows From Used In Financing Activities N/A 198,835,000.00 768,558,000.00 435,162,000.00 575,990,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A 109,752,000.00 286,770,000.00 -50,766,000.00 259,493,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -2,387,000.00 -44,006,000.00 9,969,000.00 34,094,000.00
Cash and cash equivalents 646,175,000.00 753,540,000.00 996,304,000.00 955,507,000.00 1,249,094,000.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2021

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
03.07.23 Elmar Schnee Other Buy SEK 1,092,824.52
28.12.22 RENÉE AGUIAR LUCANDER Other Other SEK 0.00
20.12.22 RENÉE AGUIAR LUCANDER Other Other SEK 14,527,500.00
20.12.22 RENÉE AGUIAR LUCANDER Other Sell SEK 13,448,750.00
20.12.22 Katayoun Fatemeh Welin-Berger Other Sell SEK 6,028,750.00
20.12.22 Katayoun Fatemeh Welin-Berger Other Other SEK 4,842,500.00
20.12.22 Fredrik Johansson Other Sell SEK 4,173,750.00
20.12.22 Fredrik Johansson Other Other SEK 3,725,000.00
20.12.22 Frank Bringstrup Other Other SEK 558,750.00
20.12.22 Katayoun Fatemeh Welin-Berger Other Other SEK 0.00

Short Interest


Current short interest

Position Holder Short Interest in Percent Date
Qube Research & Technologies Limited 0.51% 11.04.24
MILLENNIUM INTERNATIONAL MANAGEMENT LP 2.70% 09.04.24
Woodline Partners LP 1.06% 27.02.24
MILLENNIUM INTERNATIONAL MANAGEMENT LP 2.51% 26.02.24
Armistice Capital LLC 1.10% 26.02.24
Voleon Capital Management LP 0.50% 12.04.24
Woodline Partners LP 0.84% 06.03.24
MILLENNIUM INTERNATIONAL MANAGEMENT LP 2.60% 04.03.24
Armistice Capital LLC 1.09% 06.03.24
Woodline Partners LP 1.18% 23.02.24
MILLENNIUM INTERNATIONAL MANAGEMENT LP 2.43% 21.02.24
Voleon Capital Management LP 0.50% 13.03.24
Total 17.02%

Capital markets information

ISIN

SE0010441584

LEI

549300PVPZO8TNT76B58

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.